Sangamo Therapeutics, Inc.

SGMO

US8006771062

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 07:55:14 20/05/2024 pm IST			5-day change	1st Jan Change
0.617 ^USD	-5.02%		+17.88%	+19.64%

09/05	Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05	Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000	MT

Sangamo Therapeutics, Inc. Provides Earnings Guidance for the First Quarter Ended March 31, 2023

April 27, 2023 at 02:58 am IST

Sangamo Therapeutics, Inc. provided earnings guidance for the first quarter ended March 31, 2023. For the quarter, revenues are estimated to be approximately $158.0 million.

Latest news about Sangamo Therapeutics, Inc.

Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	10/05
Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000	10/05	MT
Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024	10/05	CI
Sangamo Therapeutics Prices $24 Million Registered Direct Offering	22/03	MT
Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	15/03	MT
Transcript : Sangamo Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024	14/03
Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023	13/03	CI
Sangamo Therapeutics Announces Data from Novel Proprietary Neurotropic Aav Capsid Demonstrating Industry-Leading Blood-Brain Barrier Penetration and Brain Transduction in Nhps	13/03	CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	13/03	CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03	CI
Sangamo Therapeutics Says Early Phase 1/2 Data Shows 'Durable' Safety, Efficacy of Fabry Disease Drug Candidate	06/02	MT
Sangamo Therapeutics, Inc. Announces Updated Preliminary Data from the Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, or ST-920	05/02	CI
Vaxcyte Names Chief People Officer	17/01	MT
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) dropped from NASDAQ Biotechnology Index	15/12	CI
Sangamo Therapeutics, Inc Announces Pivotal Readout in the Middle of 2024 for the Phase 3 Affine Trial	13/12	CI
North American Morning Briefing : Stock Futures -2-	08/11	DJ
Truist Securities Downgrades Sangamo Therapeutics to Hold From Buy	07/11	MT
North American Morning Briefing : Higher Bond -2-	07/11	DJ
HC Wainwright Cuts Price Target on Sangamo Therapeutics to $3 From $5, Maintains Buy Rating	06/11	MT
Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight From Overweight, Price Target is $1	06/11	MT
North American Morning Briefing : Stocks Look to -2-	06/11	DJ
Wedbush Lowers Sangamo Therapeutics' PT to $2 From $10 as Result of Valuing Potential Royalty From ST-920 Sales, Keeps Outperform Rating	03/11	MT
RBC Downgrades Sangamo Therapeutics to Sector Perform From Outperform, Cuts Price Target to $2 From $6, Cites 'Cash Preservation Mode,' Keeps Speculative Risk	03/11	MT
Transcript : Sangamo Therapeutics, Inc., Q3 2023 Earnings Call, Nov 02, 2023	02/11
Sangamo Therapeutics, Inc. Reports Impairment Charges for the Three Months Ended September 30, 2023	02/11	CI

Chart Sangamo Therapeutics, Inc.

Duration

Period

More charts

Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.

Sector

Biotechnology & Medical Research

Calendar

04/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Sangamo Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.6496 USD

Average target price

3.5 USD

Spread / Average Target

+438.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SANGAMO THERAPEUTICS, INC.	+19.64%	135M
VERTEX PHARMACEUTICALS INCORPORATED	+9.49%	115B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
ARGENX SE	-2.82%	21.96B
BIONTECH SE	-14.14%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.80%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+6.78%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.81%	12.42B

Bio Therapeutic Drugs